Want to see IN:ZIMLAB full AI Analyst Report?

Zim Laboratories Ltd. (ZIMLAB) Price & Analysis

0 Followers

ZIMLAB Stock Chart & Stats

₹71.11

-₹1.76(-1.66%)

At close: Jan 08 4:00 PM EST

₹71.11

-₹1.76(-1.66%)

Day’s Range― - ―

52-Week Range₹59.72 - ₹133.95

Previous CloseN/A

Volume52.11K

Average Volume (3M)6.28K

Market Cap

₹6.11B

Enterprise Value₹3.78K

Total Cash (Recent Filing)₹278.02M

Total Debt (Recent Filing)₹1.26B

Price to Earnings (P/E)94.9

Beta1.12

Next Earnings

Aug 06, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)1.19

Shares Outstanding53,658,490

10 Day Avg. Volume5,950

30 Day Avg. Volume6,279

Financial Highlights & Ratios

PEG Ratio-0.97

Price to Book (P/B)1.00

Price to Sales (P/S)0.80

P/FCF Ratio-39.04

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Contract Manufacturing & Diversified SalesA mixed revenue model combining branded/generic product sales and contract manufacturing provides durable diversification. Contract manufacturing yields repeatable, capacity-driven revenue and higher utilization, lowering product development risk and smoothing revenue across cycles.

Rising Equity And Moderate LeverageGrowing shareholder equity with moderate debt-to-equity supports financial flexibility. A sub-1 leverage ratio reduces refinancing risk and preserves capacity to fund investment or absorb shocks, enabling sustainable operations and strategic spending over the coming months.

Positive Operating Cash FlowConsistent positive operating cash flow shows the core business generates cash from operations, supporting working capital and day-to-day needs. This operating cash base is a durable sign of underlying demand even if free cash flow is currently stressed by investments or working-capital swings.

Bears Say

Negative And Volatile Free Cash FlowRecurrent negative and volatile free cash flow constrains the company's ability to self-fund capex, pay down debt, or return capital. Over a 2–6 month horizon, persistent negative FCF indicates reliance on external financing or working-capital adjustments, raising funding risk for investments.

Declining ProfitabilityA marked decline in net income and operating profit signals margin pressure and weakening earnings quality. Sustained profit erosion reduces reinvestment capacity and return on capital, making it harder to finance growth or improve competitive positioning over the medium term.

Modest, Inconsistent Revenue GrowthUneven and low revenue growth undermines scale benefits and limits margin expansion opportunities. Without steady top-line momentum, fixed-cost absorption and long-run profitability improvements become more difficult, constraining durable earnings growth and strategic investment ability.

Zim Laboratories Ltd. News

Zim Laboratories Schedules One-on-One Meet With Tata Asset Management

Zim Laboratories Ltd. ( ($IN:ZIMLAB) ) has issued an update. Zim Laboratories has announced that it will hold...

1M ago

Zim Laboratories to Close Trading Window Ahead of December Quarter Results

Zim Laboratories Ltd. ( ($IN:ZIMLAB) ) just unveiled an update. Zim Laboratories Limited has announced the closure of...

7M ago

ZIMLAB FAQ

What was Zim Laboratories Ltd.’s price range in the past 12 months?

Zim Laboratories Ltd. lowest stock price was ₹59.72 and its highest was ₹133.95 in the past 12 months.

What is Zim Laboratories Ltd.’s market cap?

Zim Laboratories Ltd.’s market cap is ₹6.11B.

When is Zim Laboratories Ltd.’s upcoming earnings report date?

Zim Laboratories Ltd.’s upcoming earnings report date is Aug 06, 2026 which is today.

How were Zim Laboratories Ltd.’s earnings last quarter?

Currently, no data Available

Is Zim Laboratories Ltd. overvalued?

According to Wall Street analysts Zim Laboratories Ltd.’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Zim Laboratories Ltd. pay dividends?

Zim Laboratories Ltd. pays a Annually dividend of ₹0.167 which represents an annual dividend yield of N/A. See more information on Zim Laboratories Ltd. dividends here

What is Zim Laboratories Ltd.’s EPS estimate?

Zim Laboratories Ltd.’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Zim Laboratories Ltd. have?

Zim Laboratories Ltd. has 53,658,490 shares outstanding.

What happened to Zim Laboratories Ltd.’s price movement after its last earnings report?

Currently, no data Available

Which hedge fund is a major shareholder of Zim Laboratories Ltd.?

Currently, no hedge funds are holding shares in IN:ZIMLAB

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Zim Laboratories Ltd.

Established in 1984 and based in Nagpur, India, ZIM Laboratories Limited is a pharmaceutical company that develops, produces, and supplies both finished drug formulations and pre-formulation ingredients. Operating domestically and internationally, ZIM specializes in providing technology-driven drug delivery solutions and exclusive, non-infringing manufacturing processes for generic pharmaceuticals. These offerings span semi-finished and finished product categories, encompassing forms like granules, pellets, taste-masked powders, suspensions, tablets, capsules, and oral thin films. Their extensive product range caters to various therapeutic areas, including urology, gastroenterology, cardiology, and anticoagulation, alongside antibiotics, anti-infectives, NSAIDs/pain management, and vitamins and supplements.